B M Wolpin1, E M O'Reilly2, Y J Ko3, L S Blaszkowsky4, M Rarick5, C M Rocha-Lima6, P Ritch7, E Chan8, J Spratlin9, T Macarulla10, E McWhirter11, D Pezet12, M Lichinitser13, L Roman14, A Hartford15, K Morrison15, L Jackson15, M Vincent15, L Reyno15, M Hidalgo16. 1. Dana-Farber Cancer Institute, Boston. Electronic address: bwolpin@partners.org. 2. Memorial Sloan Kettering Cancer Center, New York, USA. 3. Sunnybrook Health Science Center, Toronto, Canada. 4. Massachusettes General Hospital, Boston. 5. Kaiser Permanente Northwest Region Oncology Hematology, Portland. 6. Sylvester Comprehensive Cancer Center, University of Miami, Miami. 7. Medical College of Wisconsin, Milwaukee. 8. Vanderbilt University Medical Center, Nashville, USA. 9. Cross Cancer Institute, Edmonton, Alberta, Canada. 10. Hospital Vall d'Hebrón, Servicio de Oncología, Barcelona, Spain. 11. Juravinski Cancer Centre, Hamilton, Ontario, Canada. 12. Inserm U1071, Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France. 13. State Institution 'Blokhin Cancer Research Centre RAMS', Moscow. 14. State Healthcare Institution 'Leningrad Regional Oncologic Dispensary', Saint Petersburg, Russia. 15. Agensys, Inc., Santa Monica, USA. 16. Centro Integral Oncológico 'Clara Campal', Madrid; Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.
Abstract
BACKGROUND: We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and previously untreated, metastatic pancreatic adenocarcinoma were randomly assigned 1:2 to gemcitabine (1000 mg/m(2) weekly seven times, 1 week rest, weekly three times q4weeks) or gemcitabine plus AGS-1C4D4 (48 mg/kg loading dose, then 24 mg/kg q3weeks IV). The primary end point was 6-month survival rate (SR). Archived tumor samples were collected for pre-planned analyses by PSCA expression. RESULTS:Between April 2009 and May 2010, 196 patients were randomly assigned to gemcitabine (n = 63) or gemcitabine plus AGS-1C4D4 (n = 133). The 6-month SR was 44.4% (95% CI, 31.9-57.5) in the gemcitabine arm and 60.9% (95% CI, 52.1-69.2) in the gemcitabine plus AGS-1C4D4 arm (P = 0.03), while the median survival was 5.5 versus 7.6 months and the response rate was 13.1% versus 21.6% in the two arms, respectively. The 6-month SR was 57.1% in the gemcitabine arm versus 79.5% in the gemcitabine plus AGS-1C4D4 arm among the PSCA-positive subgroup and 31.6% versus 46.2% among the PSCA-negative subgroup. CONCLUSIONS: This randomized, phase II study achieved its primary end point, demonstrating an improved 6-month SR with addition of AGS-1C4D4 to gemcitabine among patients with previously untreated, metastatic pancreatic adenocarcinoma. ClinicalTrials.gov identifier: NCT00902291.
RCT Entities:
BACKGROUND: We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic pancreatic cancer. PATIENTS AND METHODS: Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and previously untreated, metastatic pancreatic adenocarcinoma were randomly assigned 1:2 to gemcitabine (1000 mg/m(2) weekly seven times, 1 week rest, weekly three times q4weeks) or gemcitabine plus AGS-1C4D4 (48 mg/kg loading dose, then 24 mg/kg q3weeks IV). The primary end point was 6-month survival rate (SR). Archived tumor samples were collected for pre-planned analyses by PSCA expression. RESULTS: Between April 2009 and May 2010, 196 patients were randomly assigned to gemcitabine (n = 63) or gemcitabine plus AGS-1C4D4 (n = 133). The 6-month SR was 44.4% (95% CI, 31.9-57.5) in the gemcitabine arm and 60.9% (95% CI, 52.1-69.2) in the gemcitabine plus AGS-1C4D4 arm (P = 0.03), while the median survival was 5.5 versus 7.6 months and the response rate was 13.1% versus 21.6% in the two arms, respectively. The 6-month SR was 57.1% in the gemcitabine arm versus 79.5% in the gemcitabine plus AGS-1C4D4 arm among the PSCA-positive subgroup and 31.6% versus 46.2% among the PSCA-negative subgroup. CONCLUSIONS: This randomized, phase II study achieved its primary end point, demonstrating an improved 6-month SR with addition of AGS-1C4D4 to gemcitabine among patients with previously untreated, metastatic pancreatic adenocarcinoma. ClinicalTrials.gov identifier: NCT00902291.
Authors: D C Saffran; A B Raitano; R S Hubert; O N Witte; R E Reiter; A Jakobovits Journal: Proc Natl Acad Sci U S A Date: 2001-02-13 Impact factor: 11.205
Authors: Philip A Philip; Jacqueline Benedetti; Christopher L Corless; Ralph Wong; Eileen M O'Reilly; Patrick J Flynn; Kendrith M Rowland; James N Atkins; Barry C Mirtsching; Saul E Rivkin; Alok A Khorana; Bryan Goldman; Cecilia M Fenoglio-Preiser; James L Abbruzzese; Charles D Blanke Journal: J Clin Oncol Date: 2010-07-06 Impact factor: 44.544
Authors: Moritz N Wente; Anjali Jain; Evelyn Kono; Pascal O Berberat; Thomas Giese; Howard A Reber; Helmut Friess; Markus W Büchler; Robert E Reiter; Oscar J Hines Journal: Pancreas Date: 2005-08 Impact factor: 3.327
Authors: K S McCarty; E Szabo; J L Flowers; E B Cox; G S Leight; L Miller; J Konrath; J T Soper; D A Budwit; W T Creasman Journal: Cancer Res Date: 1986-08 Impact factor: 12.701
Authors: Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: Xifeng Wu; Yuanqing Ye; Lambertus A Kiemeney; Patrick Sulem; Thorunn Rafnar; Giuseppe Matullo; Daniela Seminara; Teruhiko Yoshida; Norihisa Saeki; Angeline S Andrew; Colin P Dinney; Bogdan Czerniak; Zuo-feng Zhang; Anne E Kiltie; D Timothy Bishop; Paolo Vineis; Stefano Porru; Frank Buntinx; Eliane Kellen; Maurice P Zeegers; Rajiv Kumar; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Jose Ignacio Mayordomo; Manuel Sanchez; Berta Saez; Annika Lindblom; Petra de Verdier; Gunnar Steineck; Gordon B Mills; Alan Schned; Simonetta Guarrera; Silvia Polidoro; Shen-Chih Chang; Jie Lin; David W Chang; Katherine S Hale; Tadeusz Majewski; H Barton Grossman; Steinunn Thorlacius; Unnur Thorsteinsdottir; Katja K H Aben; J Alfred Witjes; Kari Stefansson; Christopher I Amos; Margaret R Karagas; Jian Gu Journal: Nat Genet Date: 2009-08-02 Impact factor: 38.330
Authors: Joanne W Chiu; Hilda Wong; Roland Leung; Roberta Pang; Tan-To Cheung; Sheung-Tat Fan; Ronnie Poon; Thomas Yau Journal: Oncologist Date: 2014-08-12
Authors: Elham Pishali Bejestani; Marc Cartellieri; Ralf Bergmann; Armin Ehninger; Simon Loff; Michael Kramer; Johannes Spehr; Antje Dietrich; Anja Feldmann; Susann Albert; Martin Wermke; Michael Baumann; Mechthild Krause; Martin Bornhäuser; Gerhard Ehninger; Michael Bachmann; Malte von Bonin Journal: Oncoimmunology Date: 2017-06-20 Impact factor: 8.110
Authors: Somala Mohammed; Sujita Sukumaran; Pradip Bajgain; Norihiro Watanabe; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; William E Fisher; Ann M Leen; Juan F Vera Journal: Mol Ther Date: 2017-01-04 Impact factor: 11.454